Nuformix

(NFX)
Sector: Pharmaceuticals & Biotechnology
0.05p
-0.00p -2.94
Last updated: 16:56:00

Share information

Name Nuformix
Epic NFX
Isin GB00BYW79Y38
Industry Pharmaceuticals & Biotechnology

Key numbers

Latest share price 0.05p Net gearing n/a
Market capitalisation £0.70 Debt ratio n/a
Shares in issue 819.31 Debt-to-equity ratio n/a
P/E ratio n/a Assets / equity ratio n/a
Total dividends per share n/a Price to book value n/a
Dividend yield n/a ROCE -543.34
Dividend cover n/a EPS growth n/a
Earning per share -0.08 52-week high / low 0.05p / 0.40p

Dividends

Type Ex-date Pay-date Net-dividend
No dividends declared

Contact details

Company name Nuformix
Address 6th Floor, 60 Gracechurch Street, London, United Kingdom, EC3V 0HR
Telephone +44 (0)1223 627222
Website https://nuformix.com/

Directors

Director Position
Dr Daniel Gooding Executive Director
Mr Julian Gilbert Non-Executive Chairman
Mrs Madeleine Kennedy Independent Non-Executive Director

Company financials

Assets £ (m) 2023 2022 2021
Reporting date 30/09/23 31/03/22 31/03/21
Intangible asssets and goodwill 4.08 4.15 4.19
Investments and other non-current assets n/a n/a n/a
Total non-current assets 4.08 4.15 4.19
Inventory / work in progress n/a n/a n/a
Trade and other receivables 0.07 0.2 0.03
Cash and equivalents 0.2 0.46 1.67
Other current assets and asset held for resale 0.07 0.16 0.12
Total of all assets 4.42 4.98 6.01
Liabilities £ (m) 2023 2022 2021
Short term liabilities 0.22 0.24 0.32
Long term liabilities n/a n/a n/a
Other liabilites / pension etc n/a n/a n/a
Total of all liabilities 0.22 0.24 0.32
Net assets £ (m) 2023 2022 2021
Net assets 4.2 4.74 5.69
Equity £ (m) 2023 2022 2021
Share capital 0.74 0.62 0.59
Minority interests n/a n/a n/a
Retained earnings -8.21 -7.35 -6.24
Share premium account 6.66 6.5 6.38
Total equity 4.2 4.74 5.69
Income £ (m) 2023 2022 2021
Turnover n/a n/a n/a
Operating profit -0.93 -1.27 -1.37
Pre-tax profit -0.93 -1.27 -1.38